Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2020

Details for Mechanism ID: 18217
Country/Region: Kenya
Year: 2016
Main Partner: County Government of Siaya
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,822,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $295,503
Care: TB/HIV (HVTB) $93,039
Care: Pediatric Care and Support (PDCS) $55,178
Testing: HIV Testing and Counseling (HVCT) $200,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $400,000
Treatment: Adult Treatment (HTXS) $695,513
Treatment: Pediatric Treatment (PDTX) $82,767
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: 1-9 2017 9,927
HTS_TST Age/sex: 10-14 Female 2017 1,609
HTS_TST Age/sex: 10-14 Male 2017 1,283
HTS_TST Age/sex: 15-19 Female 2017 1,323
HTS_TST Age/sex: 15-19 Male 2017 939
HTS_TST Age/sex: 20-24 Female 2017 3,303
HTS_TST Age/sex: 20-24 Male 2017 2,351
HTS_TST Age/sex: 25-49 Female 2017 5,295
HTS_TST Age/sex: 25-49 Male 2017 3,758
HTS_TST Age/sex: 50+ Female 2017 1,324
HTS_TST Age/sex: 50+ Male 2017 939
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 7,105
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 5,714
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 11,244
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 7,988
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 32,051
HTS_TST Service Delivery Point (Facility): Index testing 2017 440
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,810
HTS_TST Service Delivery Point (Facility): Other PITC 2017 239
HTS_TST Service Delivery Point (Facility): Outpatient 2017 19,015
HTS_TST Service Delivery Point (Facility): Pediatric 2017 315
HTS_TST Service Delivery Point (Facility): PMTCT 2017 1,812
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 66
HTS_TST Service Delivery Point (Facility): VCT 2017 7,812
HTS_TST Service Delivery Point (Facility): VMMC 2017 542
HTS_TST Sum of Age/Sex disaggregates 2017 22,124
HTS_TST Sum of Aggregated Age/Sex <15 2017 12,819
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 19,232
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 32,051
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 42
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 29
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 67
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 42
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 171
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 113
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 273
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 175
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 67
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 42
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 133
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 127
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 81
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 577
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 374
PMTCT_ART Already on ART at beginning of current pregnancy 2017 323
PMTCT_ART New on ART 2017 114
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 1,515
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 237
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 85
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 9
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 9
PMTCT_EID Sum of Infant Age disaggregates 2017 322
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 14
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 72
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 457
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 972
PMTCT_STAT By: Known positives at entry 2017 212
PMTCT_STAT By: Number of new positives identified 2017 74
PMTCT_STAT Number of new ANC and L&D clients 2017 1,515
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 1,515
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 2
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 28
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 153
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 30
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 10
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 54
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 9
PMTCT_STAT Sum of Positives Status disaggregates 2017 286
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 14
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 72
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 457
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 972
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 33
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 37
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 70
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 70
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 764
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 764
TB_SCREENDX Screen Result: Screened Positive for TB 2017 848
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 2,628
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 1,161
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 234
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 218
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 4,241
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 46
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 58
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 104
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 104
TX_CURR Age/Sex: <1 2017 4
TX_CURR Age/Sex: <1-9 2017 299
TX_CURR Age/Sex: 10-14 Female 2017 76
TX_CURR Age/Sex: 10-14 Male 2017 73
TX_CURR Age/Sex: 15-19 Female 2017 55
TX_CURR Age/Sex: 15-19 Male 2017 31
TX_CURR Age/Sex: 20-24 Female 2017 232
TX_CURR Age/Sex: 20-24 Male 2017 56
TX_CURR Age/Sex: 25-49 Female 2017 1,956
TX_CURR Age/Sex: 25-49 Male 2017 801
TX_CURR Age/Sex: 50+ Female 2017 385
TX_CURR Age/Sex: 50+ Male 2017 273
TX_CURR Aggregated Age/Sex: <15 Female 2017 234
TX_CURR Aggregated Age/Sex: <15 Male 2017 218
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,628
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,161
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 4,241
TX_CURR Sum of age/sex disaggregates 2017 86
TX_CURR Sum of Aggregated Age/Sex <15 2017 452
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 3,789
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 4,241
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 66
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 61
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 841
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 423
TX_NEW By Age/Sex: <1 2017 6
TX_NEW By Age/Sex: 1-9 2017 78
TX_NEW By Age/Sex: 10-14 Female 2017 19
TX_NEW By Age/Sex: 10-14 Male 2017 24
TX_NEW By Age/Sex: 15-19 Female 2017 14
TX_NEW By Age/Sex: 15-19 Male 2017 4
TX_NEW By Age/Sex: 20-24 Female 2017 80
TX_NEW By Age/Sex: 20-24 Male 2017 31
TX_NEW By Age/Sex: 25-49 Female 2017 624
TX_NEW By Age/Sex: 25-49 Male 2017 281
TX_NEW By Age/Sex: 50+ Female 2017 123
TX_NEW By Age/Sex: 50+ Male 2017 107
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,391
TX_NEW Sum of Age/Sex disaggregates 2017 1,307
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 1,391
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 3,820
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 3,820
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 211
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 197
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 2,367
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1,045
TX_PVLS Numerator: Indication: Routine 2017 3,820
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 211
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 197
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 2,367
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,045
TX_PVLS_den Denominator: Indication: Routine 2017 3,820
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 76
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 19
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 23
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 74
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 30
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 573
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 259
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 113
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 98
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 64
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 60
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 774
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 391
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 1,289
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 1,389
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 78
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 24
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 80
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 31
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 624
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 281
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 123
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 107
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 66
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 61
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 841
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 423
Cross Cutting Budget Categories and Known Amounts Total: $728,800
Human Resources for Health $637,700
Gender: Gender Based Violence (GBV) $45,550
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Gender: Gender Equality $45,550
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research